Rankings
▼
Calendar
MESO Q4 2021 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena
MESO
Mesoblast Limited
$2B
Q4 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
+188.4% YoY
Gross Profit
-$12M
-604.8% margin
Operating Income
-$19M
-966.7% margin
Net Income
-$22M
-1105.2% margin
EPS (Diluted)
$-0.34
QoQ Revenue Growth
+4.3%
Cash Flow
Operating Cash Flow
-$21M
Free Cash Flow
-$21M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$745M
Total Liabilities
$163M
Stockholders' Equity
$581M
Cash & Equivalents
$137M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$692,000
+188.4%
Gross Profit
-$12M
-$24M
+50.6%
Operating Income
-$19M
-$32M
+39.7%
Net Income
-$22M
-$33M
+32.4%
← FY 2021
All Quarters
Q1 2022 →